439126-19-9Relevant academic research and scientific papers
HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS
-
Page/Page column 148; 278; 279, (2020/06/05)
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein R1, R2, R4, R5, R6, R7, R8, R9, R10,Z, X1, X2, X3, L2, HET, n and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.
Achieving Balanced Charge Transport and Favorable Blend Morphology in Non-Fullerene Solar Cells via Acceptor End Group Modification
Hao, Minghui,Liu, Tao,Xiao, Yiqun,Ma, Lik-Kuen,Zhang, Guangye,Zhong, Cheng,Chen, Zhanxiang,Luo, Zhenghui,Lu, Xinhui,Yan, He,Wang, Lei,Yang, Chuluo
, p. 1752 - 1760 (2019/03/08)
Generally, the electron-withdrawing substitution on the end-capping group of the acceptor-donor-acceptor type small-molecule acceptor (SMA) narrows the optical bandgap, and the electron-donating group lifts the lowest unoccupied molecular orbital (LUMO) e
Polysubstituted benzocyclopentadione derivative-based A-D-A conjugated molecule and application thereof
-
, (2019/06/13)
The invention discloses a polysubstituted benzocyclopentadione derivative-based A-D-A conjugated molecule and application thereof. The application chemical structural general formula of the conjugatedmolecule is as shown in the specification. According to
THIAZOLIDINONE COMPOUNDS AND USE THEREOF
-
Paragraph 0237-0238, (2017/09/21)
A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.
